Pharmacokinetics of asciminib in the presence of <scp>CYP3A</scp> or P‐gp inhibitors, <scp>CYP3A</scp> inducers, and acid‐reducing agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents

Published:2022-05-26 Issue:7 Volume:15 Page:1698-1712
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Hoch Matthias¹,Huth Felix¹,Sato Masahiko²,Sengupta Tirtha³,Quinlan Michelle⁴,Dodd Stephanie⁵,Kapoor Shruti⁴,Hourcade‐Potelleret Florence¹

Affiliation:

1. Novartis Institutes for BioMedical Research Basel Switzerland

2. Novartis Pharma K.K. Novartis Institutes for Biomedical Research Tokyo Japan

3. Novartis Healthcare Pvt. Ltd. Hyderabad India

4. Novartis Pharmaceuticals East Hanover New Jersey USA

5. Novartis Institutes for BioMedical Research Cambridge Massachusetts USA

Funder

Novartis

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13285

Reference41 articles.

1. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

2. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase

3. Pharmacokinetics of Asciminib When Taken With Imatinib or With Food

4. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy;Blood;2024-08-29

2. The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first‐in‐class ACKR3/CXCR7 antagonist, ACT‐1004‐1239;Clinical and Translational Science;2024-07

3. Clinical pharmacokinetics and drug–drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective;Critical Reviews in Oncology/Hematology;2024-03

4. Asciminib - ABL Kinase Inhibitor in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Chemistry and Pharmacology Perspectives;Mini-Reviews in Organic Chemistry;2023-10-17

5. Leveraging the use of in vitro and computational methods to support the development of enabling oral drug products: An InPharma commentary;European Journal of Pharmaceutical Sciences;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3